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Abstract Renal transplantation (RTx) has become an accept-
ed mode of therapy in infants with severe renal failure. The
major indications are structural abnormalities of the urinary
tract, congenital nephrotic syndrome, polycystic diseases, and
neonatal kidney injury. Assessment of these infants needs ex-
pertise and time as well as active treatment before RTx to
ensure optimal growth and development, and to avoid com-
plications that could lead to permanent neurological defects.
RTx can be performed already in infants weighing around
5 kg, but most operations occur in infants with a weight of
10 kg or more. Perioperative management focuses on ade-
quate perfusion of the allograft and avoidance of thrombotic
and other surgical complications. Important long-term issues
include rejections, infections, graft function, growth, bone
health, metabolic problems, neurocognitive development, ad-
herence to medication, pubertal maturation, and quality of life.
The overall outcome of infant RTx has dramatically improved,
with long-term patient and graft survivals of over 90 and
80 %, respectively.
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Introduction
The first kidney transplantations (RTx) to infants (0–24-
month-old children) were performed in the 1960s in Minne-
apolis [1, 2]. The long-term results were at first modest and
skepticism was expressed on the rationality of treating small
children with severe renal failure. In the 1980s, technical re-
finements in dialysis therapy and post-RTx immunosuppres-
sive medication dramatically improved the overall results of
renal replacement therapy (RRT) in children and adults, and
also led to a gradual acceptance of these therapies for infants
with end-stage renal disease (ESRD).
Infants still form a minor group in pediatric RTx programs.
The incidence of children needingRRTbefore the age of 2 years
is low (7–8 per million age-related population) [3]. In a survey
from the UK and Ireland, infants accounted for only 2.8 % (19/
675) of pediatric patients with ESRD [4]. In the North
American Pediatric Renal Trials and Collaborative Studies
(NAPRTCS) registry data on 10,632 RTx recipients, children
<24 months accounted for 5.3 % of pediatric recipients [5]. In a
recent report from Europe, Australia, New Zealand, and Japan,
very few of the children who already needed RRT during the
neonatal period were transplanted before the age of 12 months,
and 80 % of these children were still on dialysis at the age of
24 months [3]. There is, however, center-based variation and
many large specialized centers performRTx for younger infants.
Recipient characteristics
The major indications for infant RTx are congenital abnormal-
ities of the urinary tract (CAKUT), congenital nephrotic syn-
drome (CNS), neonatal cortical necrosis due to thrombosis,
and autosomal recessive polycystic kidney disease (ARPKD)
[6]. A small proportion of patients have a diagnosis seen in
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older children, such as hemolytic uremic syndrome and
oxalosis. It is important to note that acute kidney injury in the
neonatal period, particularly in premature infants, often
recovers and rarely leads to ESRD and RTx in infancy. Simi-
larly, most infants with CAKUTshow slow progression and the
patients manage into adolescence or adulthood without RRT
[7]. The progression of renal failure in inherited CNS may also
be slow and RTx can be performed at the age of 2–5 years.
Active treatment of infants before RTx is important to en-
sure optimal growth and development as well as to avoid
complications (thromboses, septic infections) that could lead
to permanent neurological defects. Nutritional therapy, ade-
quate calcium and vitamin D supplementation, phosphate-
binding medication, anemia and infection, as well as manage-
ment of hypertension and proteinuria are required to prevent
the progression of renal failure [8]. Peritoneal dialysis (PD) is
mostly used for ESRD management before RTx [9] and he-
modialysis (HD) is reserved for those with problems in PD.
However, in patients with oxalosis, organic acidemias, exten-
sive history of abdominal surgery, poor socioeconomic cir-
cumstances, and fear for familial non-adherence, HD is the
preferred treatment modality. Home PD in an anuric infant is
also demanding, and improvements in pediatric HD may in-
crease its use in coming years.
Absolute contraindications for RTx are uncontrolled malig-
nancy and infection, as is the case with older patients. Children
with a history of Wilms tumor have traditionally been
transplanted 2 years after the end of cancer therapy (European
guidelines), but recent data suggest that patients with a low-risk
tumor who remain relapse-free for 6 months after treatment
might be considered for transplantation [10]. Up to 40 % of
infants with ESRD have CAKUT and the anomalies, which
were previously regarded as a contraindication to RTx, may
affect the long-term kidney graft function and survival. Preop-
erative assessment of the bladder function with urodynamic
studies is crucial in CAKUTpatients. No consensus exits wheth-
er augmentation of the bladder should be performed pre- or post-
transplant in children needing it. In our unit, infants usually
undergo ureterocystoplasty before transplantation, whereas in-
testinal cystoplasty and Mitrofanoff conduit are performed after
RTx, if needed. According to recent reports, CAKUT patients
manage quite well after RTx and augmentation does not seem to
affect the overall graft or patient survivals [11–14].
More than one-third of pediatric patients with ESRD have
co-morbidities, such as chromosomal abnormalities, syndromic
diagnosis, cerebral palsy, heart disease, and developmental de-
lay, which may severely worsen the life quality and overall
prognosis after RTx [4]. Withholding treatment from these in-
fants is a difficult ethical question with no simple answer [6]. In
general, attitudes have shifted with time and more handicapped
patients are currently accepted for RRT. An individualized de-
cision is usually made by a multidisciplinary team from the
transplant center before the commencement of chronic dialysis.
The practice in most transplant centers is to start chronic dial-
ysis only in those infants who are regarded as candidates for
transplantation. The crucial question is how and to what extent
the child and the family benefits from the operation [15].
Donor characteristics
A kidney from either of the parents is often used in infant RTx.
According to a NAPRTCS report from the US, a living donor
(LD) kidney was used in about 50 % of all pediatric RTx and
in 74 % of infant RTx [5]. In the Eurotransplant region, the
percentage of LD in pediatric RTx was much less (20 %), but
no exact figures were available for infant RTx [16]. The use of
either of the parents as an LD brings several advantages:
timing of the operation is feasible, RTx can be performed
pre-emptively, immunological matching is at least satisfactory
(one haplotype), the donor age is often low (<35 years), and
the cold-ischemia time is very short. On the other hand, the
use of a young parent for a kidney donation may raise ethical
concerns on the safety of the operation and the long-term
health of the donor. It has been shown that living kidney
donors maintain long-term renal function and experience no
increase in cardiovascular or all-cause mortality. However, in
recent surveys, donors showed a slightly increased long-term
risk for ESRD and cardiovascular complications [17, 18].
Most genetic kidney diseases manifesting soon after birth
show autosomal recessive inheritance and either parent can
be used as a donor also in these diseases, such as CNS and
ARPKD. If the disorder is not recessively inherited, genetic
consultation is important to prevent recurrences after RTx.
The allocation of deceased donor (DD) kidney grafts to
children varies worldwide. In the US, the current allocation
policy for children (Share35) emphasizes the importance of
young donors (<35 years old) and shorter waiting times over
HLA-matching [19]. This algorithm has shortened the waiting
times but increased mismatches, so that 84 % of transplants to
children are mismatched at 4–6 alleles (A,B,DR loci) [20]. A
poor match in the first graft also impairs the chances for the
second graft, which is important in infant RTx, as these patients
inevitably need another graft later in life [21]. In most Euro-
pean centers HLA-A, B, and DR matching is still an important
part of organ allocation [19, 22], which may be reflected in the
better long-term survival rates in Europe [23]. The great
majority of kidney grafts come from brain-death donors, and
the experience of donation after cardiac death (DCD) is still
limited in pediatric and especially infant RTx [24].
Traditionally, kidneys from young pediatric donors
(<5 years of age) have not been used in infant RTx, as the
early reports showed a decreased graft survival rate caused by
infections and technical problems [25–28]. However, more
recent data indicate that a pediatric donor organ can adapt
the glomerular filtration rate (GFR) with the recipient’s
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growth and these grafts would provide even better long-term
results [29, 30]. En bloc kidneys from infant donors have been
used for adult recipients and more recently also for older pe-
diatric recipients (>4 years of age), but, to our knowledge, not
for infant recipients [31].
ABO-blood group compatibility between the donor and
recipient has traditionally been required in RTx. However,
ABO-incompatible (ABOi) renal transplantation has become
more popular and hundreds of patients have been successfully
transplanted across the ABO-barrier [32–34]. Infants have low
levels of ABO-antibodies and are immunologically good can-
didates for ABOi-transplantation. This is evident in heart
transplantations, where most ABOi recipients are infants
[35]. Thus, it is to be expected that the use of ABOi donors
will increase in infant RTx during the coming years.
Timing of transplantation
Timing of the infant RTx is an important issue. Early transplan-
tation is favored by the fact that transplanted children showbetter
growth, development, and quality of life compared to dialysis
patients, and they avoid many complications, such as peritonitis
and venous access problems. Both intra- and extraperitoneal
placement of the graft can be used (see below) and young infants
weighing <5 kg have been successfully transplanted [1, 36, 37].
Very early transplantation carries, however, added risks and
needs multidisciplinary expertise. Adult-sized grafts have been
successfully transplanted into infants weighing 7–10 kg, but a
common practice is to perform the operation when a child has
reached the weight of 10–20 kg when extraperitoneal placement
of the kidney is feasible [36]. This approach was evident in two
large international surveys of about 400 infants with ESRD [3,
38]. Besides weight, the child’s height, body shape, and size of
blood vessels play a role in the planning of the operation. In
patients suitable for RTx, long dialysis period does not bring
additional value and an early operation is preferred, especially
in large specialized transplant centers.
In CNS patients with severe proteinuria, bilateral nephrec-
tomy can be performed at the age of 6–9 months followed by
dialysis therapy for some months before an early RTx (weight
around 10 kg). The other strategy is to perform a unilateral
nephrectomy and wait for the development of ESRD. In this
case, RTx can be postponed to the age of 2–5 years [39].
According to a recent survey of EDTA-registry data, both
approaches seem to result in equally good long-term outcome
(T. Hölttä, personal communication, March 20, 2015).
Surgery
In infant RTx, a kidney graft can be placed intra- or
extraperitoneally (Fig. 1 and Table 1). In the former approach,
a midline incision is made on the abdominal wall and the graft
is placed into the right side of the peritoneal cavity [1, 2]. After
mobilizing the right colon and terminal ileum, the donor renal
vein and artery are anastomosed to the recipient vena cava and
aorta, respectively, in an end-to-side technique. The donor’s
ureter is implanted into the recipient’s bladder using either a
Ledbetter–Politano procedure or one of its modifications.
Temporal stenting may be used to reduce the risk of ureteral
stenosis, especially when suboptimal arterial blood flow in the
distal ureter is suspected. An adult-sized kidney can occupy
the entire right side of the abdomen leading to bowel dysfunc-
tion and ileus, especially during the early post-operative
phase. The lateral edge of the allograft is usually easily acces-
sible to an ultrasound-guided renal biopsy [1, 2, 40].
When an extraperitoneal placement is used, an incision is
made above the right groin (or left side in re-RTx). The perito-
neum is mobilized from the anterolateral and posterior abdom-
inal wall, exposing the posterior muscles and the great vessels.
The kidney graft artery and vein are usually anastomosed with
the common iliac artery and vein, respectively. The sites for
anastomoses, however, depend on the relative sizes of the ves-
sels of the graft and the recipient. The greater the size mismatch
is, the more proximal recipient vessel anastomoses are used.
Still, the available space for an adult-size kidney may present
a problem, and to avoid pressure and circulatory problems, it is
sometimes safer to close the fascia a few days after the primary
operation [30, 41]. To ensure urine flow, a transvesical catheter
is usually placed in the bladder. In infants with CAKUT, there
are different intra- and extravesical techniques to make a ureter-
bladder anastomosis; the choice depends on the anatomy and
previous surgery [13].
Peri-and postoperative management
While intraoperativemanagement of the recipient follows nor-
mal anesthetic practice, maintenance of sufficient perfusion of
the transplanted kidney is crucial. Sufficient cardiac output
and volume overload is needed to ensure adequate perfusion
of the allograft. The cardiac output of infants must double in
order to perfuse the adult kidney adequately [42]. It is desir-
able to maintain a central venous pressure above 10 cm H2O
prior to unclamping and the mean arterial pressure at more
than 60 mmHg. Intravenous crystalloid or colloid solutions
(Ringersteril, 0.9 % normal saline, 4 % albumin) and mannitol
may be used to promote urine output according to the practice
of the transplant center.
After the operation, attention to the intravascular volume
and electrolyte and acid–base stability is essential to ensure
good renal function. During the first days, polyuria is common
and urine output can be replaced by 0.45 % (or 0.9 %) saline
solution. Additional fluid infusions may be given if urine out-
put drops. Intravenous furosemide boluses can be given if
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dehydration is excluded. Weight measurements, blood pres-
sure monitoring, and follow-up of fluid input and output are
important for securing the safety of excessive fluid adminis-
tration (2500 ml/m2) [42]. Infant recipients are often slightly
oedematous (0.5–1.0 kg) and hypertensive during the first
postoperative days. Systolic blood pressure values of 100–
120 mmHg are, however, allowed in this early phase.
Monitoring of serum sodium, potassium, bicarbonate, calci-
um, phosphorous, and magnesium is essential. Due to variation
in the urine output (heavy diuresis, delayed graft function) and
use of diuretics and calcineurin inhibitors (CNI), any of these
electrolytes may need supplementation. On the other hand, slight
hyperkalemia (5–6 mmol/l) is very common during the first
weeks but rarely needs therapy. Oral phosphate and magnesium
supplementations may be needed for several months, and
calcium-vitamin D supplementation can be given permanently.
Hypertension secondary to high fluid intake, corticoste-
roids, and CNI is common after RTx. Also, the preoperative
blood pressure of both the donor and recipient have an impact
on the post-transplantation blood pressure values. Calcium-
channel blockers (amlodipine and nifedipine) are widely used
in pediatric RTx patients. Antibiotic prophylaxis is given as
long as the bladder catheter is kept in situ. Infants without
urine output before the operation have a small shrunken uri-
nary bladder, and the catheter is closed for increasing time
periods before its final removal. The use of anticoagulation
(enoxaparin, ASA) postoperatively is decided individually.
Our practice is to start anticoagulation if poor blood flow in
the ureter is suspected or a small pediatric graft is used. Pro-
phylaxis against Pneumocystis jirovecii (co-trimazole) and cy-
tomegalovirus (CMV) (ganciclovir/valganciclovir) are rou-
tinely used by most centers for 3–12 months after the opera-
tion. Infants are often CMV negative at the time of RTx and
receive a CMV positive graft from an adult donor and, thus,
have a clear risk for CMV infection.
Immunosuppressive medication protocols are center-spe-
cific. This is so for both perioperative induction therapy and
maintenance medication. In the NAPRTCS report from 2010,
no induction was used in 54%, antithymocyte globulin (ATG)
in 27 %, and basiliximab (anti-IL2-receptor antibody) in 10 %
of the US centers [5]. Triple medication with CNI (tacrolimus
or cyclosporine A (CsA)), antimetabolite (mycophenolate mo-
fetil (MMF) or azathioprine) and glucocorticoid (prednisone
or methylprednisolone) is typically used as an early mainte-
nance medication. According to the NAPRTCS report, immu-
nosuppression at 30 days after RTx included prednisone in
50 %, tacrolimus in 60 %, MMF in 60 %, and CsA and aza-
thioprine in only a small percentage in the US centers [5].
In general, infants need the same medication as older pedi-
atric RTx patients. In our center, the early immunosuppressive
protocol is still CsA-based, as the dosing in the smallest re-
cipients is easier and more accurate with CsA as compared to
tacrolimus. Due to the faster metabolic capacity of smaller
children, CsA is at first given to the infants three times a day
[43]. Steroid-free protocols are successfully used in many
transplant centers to avoid the side effects of glucocorticoids
Fig. 1 In infants, the kidney graft
can be placed intraperitoneally (a)
or extraperitoneally (b)
Table 1 Important short-term issues in infant renal transplantation
Choice of intra- vs. extraperitoneal placement of the graft
Abundant fluid administration intra- and postoperatively
Monitoring and supplementation of electrolytes (Na, K, Mg, Pi, HCO3)
Regular weight and blood pressure measurements
Ultrasound monitoring for blood circulation, pelvic/ureteral diameters,
perinephric fluid collections
Core needle biopsy if an acute rejection is suspected
Monitoring of CNI-levels
Infection surveillance and prophylaxis
CNI calcineurin inhibitors
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[44]. The other possibility is to switch to low-dose (0.1 mg/kg/
day), every-other-daymedication, which also effectively abol-
ishes the steroid side effects [45, 46].
Surgical complications
The most common cause of early graft failure in young
recipients is graft thrombosis. In the original reports on infant
RTx, frequencies up to 30 % were reported, but recently the
incidence of thrombosis has been 2–10 % in infants [47, 48].
The smaller size of the blood vessels predisposes infants to
thrombotic events, and investigation of the size of blood ves-
sels in the recipient before RTx is recommended. Also, perfu-
sion and preimplantation damage, long ischemia time, hypo-
tension and hypoperfusion of the graft, as well as immune
mechanisms have been associated with the development of
thrombosis [47].
Venous thrombosis leads to instant swelling of the graft and
is easily clinically diagnosed. The diagnosis of arterial throm-
bosis is made by ultrasound (US). Arterial and venous throm-
boses often result in graft loss. Thus, it is essential to evaluate
perfusion of renal vessels by US immediately after operation
and on a daily basis thereafter. The US demonstrates alter-
ations in renal hemodynamics such as reduction, absence or
reversal of diastolic flow, which is seen as a change in the
resistance index (RI). RI changes can be caused by parenchy-
mal edema (rejection), external compression of vasculature
structures, or venous kinking. When an adult-sized kidney is
transplanted into an infant, the RI values are often higher than
with older children [49]. Marked changes in the RI value, not
the baseline, are important.
The postoperative US monitoring may reveal peritransplant
fluid collection, such as a seroma, blood clot, urinoma, or
lymphocele. The first two do not usually cause urinary obstruc-
tion and seldom need intervention. On the other hand, urinoma
and lymphocele located between the kidney graft and urinary
bladder may cause ureteral stenosis and obstruction leading to a
dilatation of the ureter and hydronephrosis of the graft. These
require surgical drainage and in some cases laparoscopic fen-
estration of the lymphocele into the peritoneal cavity is needed.
Disintegration of the distal ureter or rupture of the bladder
can cause a urine leak. If urinary extravasation is diagnosed,
exploration and correction of the underlying problem is indi-
cated. Kinking of the ureter or blockage at the implantation
site of the ureter may need temporary ureteral stenting to en-
sure adequate urine flow. Fibrosis of the distal ureter following
ischemia resulting from compromised ureteral arterial flow
may lead to gradual stenosis or obstruction of the ureter. Tem-
porary management includes placement of a percutaneous
nephrostomy or ureteral stent. Operative management in-
cludes ureterocystostomy and uretero- or pyeloureterostomy
using the native ureter.
Acute rejection
Improvements in immunosuppressive medication have result-
ed in a remarkable decrease in the incidence of acute rejection
(AR) in pediatric RTx patients. In the latest NAPRTCS-
registry (years 2007–2010), the probability of AR during the
first 12months had decreased to 8.6 and 16.6% in LD andDD
transplantations, respectively [5]. An interesting question is
whether infants have a different risk for rejection as compared
to older children. Previously, heightened immunoactivity was
suggested. However, in the recent registry data, infants
showed relative hazard rates of 0.51 and 0.89 for the first
AR in LD and DD transplantations, respectively, indicating
that the risk was moderately decreased. In our experience,
infants are not very different from older children in developing
AR. A renal biopsy is mandatory for a diagnosis of AR in
infants, since a large adult-sized kidney can undergo substan-
tial damage before a rise in serum creatinine occurs [50, 51].
The literature on acute antibody-mediated rejection in pe-
diatric and especially infant RTx is still scarce. It is to be
expected that preformed HLA-antibodies are less common
in infants than in older children. De novo donor-specific anti-
bodies (DSA) can be detected also in pediatric patients and
they have been associated with decreased long-term graft
function [52, 53]. However, contradictory results on the im-
portance of DSA have been published [54].
Infections
Peri- or postoperative bacterial or yeast infections are not com-
mon in infant RTx recipients. Urinary tract infections (UTI)
are, however, quite frequent and associated with vesicoureteral
reflux to the graft and sometimes to native kidneys. In the study
of Their et al., the frequency of UTI in RTx children <2 years
and 2–5 years of age was 0.3 and 0.1 episodes/patient year,
respectively, suggesting that infants are not especially prone to
UTI [55]. Increased occurrence of UTI has been reported in
RTx patients with CAKUT and bladder dysfunction [14]. In
recent reports, the UTI frequency in patients with diverted or
augmented bladder was, however, not exceptionally high [13,
56]. Management of UTI is important, as repeat episodes may
hasten deterioration of graft function andwith some infants it is
wise to use antibiotic prophylaxis.
Viral respiratory tract infections (URI) are by far the most
frequent infectious complication of RTx infants. In our expe-
rience, complicated respiratory infections among RTx recipi-
ents are, however, rare, and even small children recover from
URI quite normally; hospitalization of a patient due to URI is
rarely needed [55]. As is the case in the general population,
gastrointestinal infections are not rare among small transplant
children [55]. Diarrhea and vomiting may require intravenous
fluid therapy and medication as well as intensified drug
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monitoring. Even a moderate dehydration often leads to tem-
porally increased creatinine levels in RTx infants.
CMV, Epstein–Barr virus (EBV), and Polyomaviruses (PV)
(nephritis caused by BK virus and less often JC virus) are a
major concern in pediatric RTx patients of all ages. Since most
infants are seronegative for these viruses at the time of trans-
plantation, primary infection after RTx is common. Monitoring
of these viruses by a PCR method from blood or plasma sam-
ples is highly recommended [57]. CMV viremia is rare in pa-
tients receiving valganciclovir prophylaxis, but after stopping
the medication, subclinical or clinical viremia is quite common.
Management of PVand EBV viremias is more complicated,
as the there is no effective therapy for either virus, with the
exception of reduction of the immunosuppressive medication.
In the case of PV infection, nephritis caused by this virus can be
verified by kidney biopsy, which should be taken when signif-
icant viremia (>10,000 copies/ml) or signs of renal graft dys-
function are noticed. Constant EBV viremia may lead to the
development of post-transplant lymphoproliferative disease
(PTLD) and increasing EBV DNA levels usually require reduc-
tion of immunosuppressive medication, which increases the risk
of rejection [58]. In a recent survey, the relative hazard for PTLD
was 5.3-fold higher in children aged <6 years of age versus those
>12 years, and EBV seronegative subjects had a 4.7-fold higher
risk compared to EBV-positive subjects [58]. In our center,
PTLD has been diagnosed in seven of the 252 RTx patients
(3.7 %) and four of these had received their kidney graft as
infants. Excellent articles on the management of CMV, EBV,
and PV infections have recently been published [57–61].
Long-term problems
While the short-term results of infant RTx are nowadays ex-
cellent, the major issue is how these children manage in the
long run (Table 2). Patients who received RTx at young age
need follow-up and therapy for several decades, not several
years. Important issues are long-term graft function, growth,
pubertal maturation and fertility, bone health, metabolic prob-
lems, neurocognitive development, adherence to medication,
and quality of life.
Graft function
The most important cause of late graft failure is chronic renal
allograft injury that accounts for one-third of the graft losses in
pediatric RTx patients [5, 62]. The term includes chronic active
T-cell-mediated and antibody-mediated rejections, arteriopathy
and interstitial fibrosis/tubular atrophy with no specific etiology
[63, 64]. According to our experience, chronic allograft injury
is detected to a similar extent in the allografts of patients who
received their transplant in infancy or later in childhood [65].
This is reflected in the similar pattern of GFR deterioration with
time, as shown in Fig. 2. The mean annual decline of measured
GFR is 2.2 ml/min/1.73 m2, indicating that infant RTx recipi-
ents need a new graft as young adults.
Growth
Most infants are growth-deficient at the time of RTx. The
NAPRTCS registry data showed that the youngest recipients
(1–2 years) had a negative height Z score (hSDS) of –2.2 at the
time of transplantation, but exhibited substantial catch-up
growth (up to –1.4 SD) for the initial 3–4 years after transplan-
tation before plateauing and subsequently exhibiting a decline
in the height score (–1.7 SD at 6 years) [66]. In the study by
Qvist et al., children <2 years of age had a mean hSDS of 1.1
both at RTx and 7 years after the operation [67]. Growth after
RTx is satisfactory, but the final height attained by most recip-
ients is not their calculated target height [68, 69]. The results
Fig. 2 Measured annual glomerular filtration rate (GFR) in 61 patients
transplanted before the age of 24 months and in 127 patients transplanted
after the age of 24 months (Children’s Hospital, Helsinki)
Table 2 Important long-term issues in infant renal transplantation
Graft function
Viral surveillance
HLA-antibody surveillance
Growth
Motor development
Neurocognitive development
Cosmetic side effects of the medication
Bone health
Metabolic risk factors
Life quality
Pubertal development
Adherence to medication
Programmed transition to an adult unit
HLA human leukocyte antigen
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emphasize the importance of the preoperative management of
infants with ESRD or nephrosis [70]. After RTx, allograft func-
tion and steroid exposure have an impact on growth, and in
those with poor growth, steroid dosing should be minimized.
Especially in adolescence, short stature can have major conse-
quences on quality of life and self-esteem.
For the most stunted patients, recombinant growth hor-
mone (GH) therapy has been used for over 20 years, and the
therapy has been effective in inducing substantial catch-up
growth in most patients. There have, however, been some
concerns that the therapy might induce rejections or PTLD.
A recent meta-analysis confirmed that GH therapy promotes
growth velocity in RTx children [71]. In this analysis, the risk
for rejection was slightly increased (risk ratio 1.56) in patients
receiving GH. On the other hand, a report from Australia and
New Zealand did not find a relationship between GH use and
PTLD [72]. Monitoring of growth for at least 1 year post-
transplantation is recommended before starting (or re-
starting) GH therapy. One practical problem with GH therapy
is that it is expensive, and must be continued for years, as the
positive effect stops when the therapy is discontinued.
Pubertal development
Besides growth, pubertal developmental and fertility are im-
portant long-term issues in adolescents and adults who were
transplanted as infants. Delayed puberty has been reported in
several studies on pediatric RTx patients [73, 74]. In a recent
report by Tainio et al., children who underwent RTx at a
young age (most patients <2 years at RTx) had quite normal
puberty and reached it earlier than those transplanted at later
age (12.3 vs. 13.4 years) [69]. Twenty percent of boys and
none of the girls had a delayed onset of puberty. The bone age
was delayed in practically all and final height was achieved at
18.1 and 16.0 years in boys and girls, respectively, which
provides growth potential for a longer time. In a subsequent
study, the reproductive endocrine function of adult men who
received RTx as small children was, however, impaired. De-
spite quite normal sex hormone levels, only one-fifth of these
young men had normal sperm counts [75]. Studies on the
fertility of young women transplanted in early childhood are
still required.
Bone health
Mineral and bone disorder in RTx children may result in de-
creased bone mineral density (BMD), fractures, bone pain,
and growth failure [76, 77]. In a cross-sectional study by Valta
et al., vertebral fractures were observed in 8% of RTx children
(median age 12 years) and the majority of them were asymp-
tomatic. The height-adjusted BMD in lumbar spine was satis-
factory and similar in patients transplanted before the age of
2 years as compared to those transplanted at a later age (–0.5
SD vs. –0.4 SD) [78]. Female sex and age >15 years as well as
high PTH levels were significant predictors of low BMD. As
the basis for lifelong bone health is established in childhood
and adolescence, follow-up measurement of bone mineraliza-
tion by DXA and spinal imaging of vertebral fractures is war-
ranted [79]. Therapeutic efforts to reduce MBD include vita-
min D, calcium, and sometimes phosphate supplementation.
Metabolic risk factors
In children transplanted at a very young age, avoidance of
metabolic risk factors such as obesity, hypertension, dyslipid-
emia, and impaired glucose metabolism, is important in two
respects. First, these factors may adversely affect the graft
function and, secondly, they may lead to early cardiovascular
problems that can impair later therapies (retransplantation in
adulthood). The data on metabolic risk factors among pediat-
ric RTx patients are still limited. In a cohort of patients mostly
transplanted before the age of 2 years, metabolic syndrome,
overweight, hypertension, and type 2 diabetes were observed
in 14–19%, 20–23%, 61–87%, and 3–5 % of patients at 1.5–
5 years after RTx, respectively [45]. Higher incidences of
these risk factors, however, have been reported in pediatric
RTx patients [80–83]. Thus, the follow-up of blood pressure
is crucial and antihypertensive medication is required in the
majority of the patients. In addition, significant proteinuria is
associated with worse outcome and should be taken into ac-
count in the medication [84].
Neurocognitive development
Children with renal failure from infancy would be expected to
have a less favorable neurodevelopmental prognosis. This is
especially so in patients with neurological comorbidities and
those who suffered from thrombotic events before RTx. How-
ever, in many children, the neuromotor development after
RTx is satisfactory. In a recent report, patients (mean age,
11 years) diagnosed with ESRD as infants had intellectual
and metacognitive functioning significantly lower than sibling
controls with the mean Full Scale IQ scores of 78 and 94,
respectively [85]. In a report of 33 school-aged children
transplanted before the age of 5 years, younger age at RTx
was associated with higher scores on several parameters. The
mean intelligent quotient (IQ) was 87, and 6–24 % showed
impairment in neuropsychological tests. About 80 % of the
children attended normal school and 76 % had normal motor
performance [86]. In another study, 50 children transplanted at
an early age were assessed at a mean age of 11.1 years. The
RTx group scored generally lower than the control group on
neuropsychological assessment. The difference was evident in
both the verbal and visuospatial domains and verbal working
memory. A better cognitive outcome was associated with the
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absence of neurological co-morbidity, younger age, shorter
disease duration, and sustained kidney function [87].
Life quality
The ultimate goal of RTx is to provide a good overall well-
being of the patients. In general, the psychosocial outcome
after RTx children is satisfactory, so that most patients and
their parents have a good life according to themselves [88].
In a study of psychosocial adjustment in school-aged children,
most of whom had received an RTx during infancy, the health-
related measure was comparable to normal school children
[89]. The reported results have, however, been variable, and
in a quite recent study, RTx children (aged 3–19 years)
showed higher levels of mental health problems and lower
quality of life as compared to controls [90]. Quality of life
has also been studied in young adults who received RTx in
childhood. Again, the results are varied, but most patients are
quite satisfied with their life [91–93]. Adolescents who re-
ceived RTx in infancy, and do not remember the Bhard times^
before and after RTx, need thorough surveillance for adher-
ence to medication and help in transition to an adult unit.
Comorbidities significantly affect quality of life and many
disabilities originate from the time before RTx [94]. Although
the quality of life is not necessarily correlated to the degree of
physical disability, much effort should be made to diminish
the complications, which have an impact for later adjustment.
Continuous multidisciplinary support, follow-up, and educa-
tion are needed to cope with this problem.
Key summary points
– In infants, congenital anomalies of the kidneys and uri-
nary tract (CAKUT) and congenital nephrotic syndrome
are the most common causes of renal transplantation. Ac-
tive treatment of an infant with renal failure is important
to ensure optimal postoperative outcome.
– Renal transplantation with intraperitoneal engraftment
can be performed on an infant weighing 6–10 kg. If the
graft is placed extraperitoneally, transplantation is usually
performed when the child has reached the weight of 10–
15 kg. Intra- and perioperative management of a recipient
is focused on maintenance of sufficient perfusion of the
transplanted kidney and avoidance of thrombosis, rejec-
tions, and infections.
– Infants need life-long immunosuppressive medica-
tion, including calcineurin inhibitor, antimetabolite,
and corticosteroid. Management of the many side ef-
fects of these drugs is important to ensure good
growth and development.
Conclusions
The overall outcome of infant RTx has dramatically improved
such that several registry data and single-center reports show
10-year patient and graft survivals of over 90 and 80 %, re-
spectively [95]. Short-term problems after transplantation are
more common in infants than in older children [5], but the
long-term outcome figures in infants are better, with a relative
hazard for graft failure being about 0.2–0.6 in infants as com-
pared to adolescents [96]. Infants receiving living donor grafts
have estimated graft half-life of almost 30 years [96]. Careful
follow-up of subjects who received kidney grafts as small
children is needed to ensure optimal growth and development,
as well as good quality of life in adulthood when the second
kidney transplantation is required.
Multiple-choice questions (answers are supplied
following the reference list)
1) Infants form a special group of pediatric renal transplant
recipients. Of all pediatric recipients they account for:
a. <10 %
b. 10–19 %
c. 20–29 %
d. 30–39 %
e. >40 %
2) Acute rejections are nowadays diagnosed less often than
before. Their frequency in infant renal transplantation is:
a. 40–60 %
b. 30–39 %
c. 20–29 %
d. 5–19 %
e. < 5 %
3) Infant kidney transplant recipients are often seronegative
for Epstein–Barr virus (EBV) at the time of transplanta-
tion. The risk for post-transplant lymphoproliferative dis-
order (PTLD) in seronegative recipients, as compared to
seropositive subjects, is:
a. 2-fold
b. 5-fold
c. 8-fold
d. 10-fold
e. 20-fold
4) In infant renal transplantation the major cause of early
graft loss is:
a. acute rejection
b. unrinary tract infection
c. ureteral stenosis
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d. lymphocele
e. vascular thrombosis
5) The overall outcome of renal transplantation in infants is
nowadays good. Graft survival ten years after the opera-
tion is:
a. 50 %
b. 60 %
c. 70 %
d. 80 %
e. 99 %
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